RVMD — Revolution Medicines Cashflow Statement
0.000.00%
Last trade - 00:00
- $6.85bn
- $5.00bn
- $11.58m
- 48
- 11
- 96
- 50
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -47.7 | -108 | -187 | -249 | -436 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 3.53 | 12.7 | 27 | 32.8 | 42.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.46 | -7.93 | 8.72 | -13.1 | 40.7 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -49.6 | -100 | -147 | -224 | -351 |
Capital Expenditures | -2.59 | -2.93 | -6.53 | -10.8 | -7.73 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -99.4 | -231 | -136 | -13.3 | -335 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -102 | -234 | -142 | -24.1 | -343 |
Financing Cash Flow Items | -1.6 | 0 | -0.424 | 0.042 | 837 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 98.7 | 423 | 294 | 301 | 1,229 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -52.9 | 88.5 | 4.88 | 52.9 | 536 |